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Polychlorinated dibenzo-p-dioxins (PCDDs),
polychlorinated dibenzofurans (PCDFs), and
polychlorinated biphenyls (PCBs) are envi-
ronmental endocrine disruptors that have
half-lives of 7–10 years in the human body
and exhibit adverse effects on development
(Kogevinas 2001), endocrine systems (Wang
et al. 2005), neural systems (Jacobson and
Jacobson 1996, 2002), immunity (Baccarelli
et al. 2002), and reproduction (Guo et al.
2000), even at background exposure levels
(Brouwer et al. 1999). Women who were
accidentally and heavily exposed to a high
dose of dioxins in an industrial accident (fac-
tory explosion) in Seveso, Italy, developed
premenopausal breast cancer at a rate 2-fold
higher than controls (Warner et al. 2002).
Thus, studies are warranted on the carcino-
genetic mechanism(s) of dioxins and dioxin-
like compounds (Schecter and Olson 1997;
Schwarz and Appel 2005; Warner et al.
2002).
Recent reviews have suggested 2,3,7,8-
tetrachlorodibenzo-p-dioxin (TCDD) as a
group 1 carcinogen (Steenland et al. 2004).
However, more epidemiologic evidence is
required for an unequivocal classification.
The uncertainty is due to inconsistent find-
ings in human studies. Because the actual
exposure usually involves multiple congeners,
a more inclusive exposure investigation in
humans is important.
Estrogen levels have been positively asso-
ciated with breast cancer risk in a prospective
cohort on the island of Guernsey in the
English Channel (reviewed by Clemons and
Goss 2001). The carcinogenic effect of estro-
gens may be attributed to the initiation of
estrogen metabolism by cytochrome P450
enzymes CYP1B1, CYP1A1, and CYP1A2
(Badawi et al. 2001; Cavalieri et al. 2001;
Nebert and Russell 2002; Yager 2000). As
shown in Figure 1, dioxins, PCDFs, and
some PCBs, can induce CYP1A1, CYP1A2,
and CYP1B1 gene expression by serving as
aryl hydrocarbon receptor (AhR) agonists
(Safe 2001). CYP1A1 and CYP1B1 catalyze
hydroxylation of the A-ring of estradiol (E2) to
form the catechol estrogen 2- or 4-hydroxyl
estradiol (2-OH-E2 or 4-OH-E2, respectively).
The quinone metabolites of 4-OH-E2 can
interact with DNA and, in turn, lead to
depurination of DNA—a potential mutagene-
sis event (Cavalieri et al. 2001). Indeed, a high
4-OH-E2:2-OH-E2 ratio has been suggested as
a marker for breast neoplasm (Liehr 1999).
Incubation of human mammary epithelial
MCF-7 and MCF-10A cells with dioxins
resulted in a concentration-dependent decrease
in the ratio of 4-methoxy-E2 (4-MeO-E2) to
2-methoxy-E2 (2-MeO-E2) as an indication of
decreased 4-OH-E2:2-OH-E2 (van Duursen
et al. 2003). However, no comparable human
studies have been reported to date.
In Taiwan, the onset of breast cancer
tends to occur at a younger age than in
Western countries, and young patients show
poorer prognostic features than their older
counterparts (Cheng et al. 2000). New bio-
logic markers to identify high-risk groups are
urgently needed so that the young high-risk
patients can receive treatment as early as pos-
sible. In premenopausal women, the levels of
sex steroid hormones change dramatically
during the menstrual cycle. Thus, it is very
difficult to correlate the alterations of hor-
mone status with exposure of environmental
endocrine disruptors. In contrast, concentra-
tions of steroid hormones are much more sta-
ble during the third trimester of gestation.
The present study is aimed to determine
estrogen metabolites in maternal blood col-
lected at the third trimester and to examine a
possible correlation of the metabolite proﬁle
with placental levels of PCDDs/PCDFs and
PCBs. This may help answer the question of
whether 4-OH-E2:2-OH-E2 is a good marker
to identify the group at high risk for breast
cancer in populations exposed to dioxins and
dioxin-like compounds.
Materials and Methods
Study population and materials. The study
population was described previously (Chao
et al. 2004; Wang et al. 2004). In brief, sub-
jects were healthy pregnant women from the
general population who were recruited in a
medical center located in a suburban setting
of central Taiwan. Women (n = 763) were
recruited between December 2000 and
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Polychlorinated dibenzo-p-dioxins (PCDDs, dioxins), polychlorinated dibenzofurans (PCDFs), and
polychlorinated biphenyls (PCBs) are environmental endocrine disruptors that have half-lives of
7–10 years in the human body and have toxicities that probably include carcinogenesis. A high ratio
of 4-hydroxyl estradiol (4-OH-E2) to 2-hydroxyl estradiol (2-OH-E2) has been suggested as a
potential biomarker for estrogen-dependent neoplasms. In this cohort study of maternal–fetal pairs,
we examined the relationship of PCDD/PCDF and PCB exposure to levels of estrogen metabolites
in the sera of 50 pregnant women 25–34 years of age from central Taiwan. Maternal blood was col-
lected during the third trimester, and the placenta was collected at delivery. We measured 17 dioxin
congeners, 12 dioxin-like PCBs, and 6 indicator PCBs in placenta using gas chromatography cou-
pled with high-resolution mass spectrometry. Estrogen metabolites in maternal serum were ana-
lyzed by liquid chromatography tandem mass spectrometry. The ratio of 4-OH-E2:2-OH-E2
decreased with increasing exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin (β = –0.124, p = 0.004
by the general linear regression model, R = 0.4). Meanwhile, serum levels of 4-OH-E2 increased
with increasing concentrations of high-chlorinated PCDFs (i.e., 1,2,3,4,6,7,8-hepta-CDF:
β = 0.454, p = 0.03, R = 0.30). Altered estrogen catabolism might be associated with body burdens
of PCDDs/PCDFs. Our study suggests that exposure to PCDDs/PCDFs signiﬁcantly affects estro-
gen metabolism. Therefore, PCDD/PCDF exposure must be considered when using the OH-E2
ratio as a breast cancer marker. Key words: breast neoplasm, carcinogenic marker, estrogen catabo-
lism, estrogen metabolism, polychlorinated biphenyls, polychlorinated dibenzodioxins, polychlori-
nated dibenzofurans. Environ Health Perspect 114:740–745 (2006). doi:10.1289/ehp.8809
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interview data at obstetric clinics during rou-
tine health checkups. All of the participants
completed questionnaires concerning maternal
age, occupation, disease history, cigarette
smoking, alcohol consumption, dietary habits,
and baby’s stature. Of those recruited,
610 women were ultimately enrolled in the
study. Among these, 430 completed the ques-
tionnaire and their placentas were collected,
and 250 participants provided sufficient
maternal venous blood for the chemical analy-
ses. Placental samples and maternal blood
samples were analyzed from 50 randomly
selected individuals in this group. The placen-
tal samples were analyzed for PCDDs/PCDFs
and PCBs, and the blood samples were ana-
lyzed for estrogens and their metabolites.
The study protocol was reviewed by the
Human Ethics Committee of the National
Health Research Institutes in Taiwan. We fol-
lowed the code of ethics established by the
Helsinki Declaration of 1964 and revised in
2000 (World Medical Association 2000).
Each participant provided informed consent
after receiving a detailed explanation of the
study and potential consequences.
Maternal venous serum was collected at
weeks 28–32 of gestation. Placental samples
were collected at delivery. The delivered pla-
centa was cleaned and rinsed with normal
saline in the clinic ward. Placental samples
were frozen (–20°C) as soon as possible and
during transport to the central laboratory in
the National Health Research Institutes. At
the laboratory, each placenta was divided into
four equal parametric parts. One of the quar-
ters was minced and put in sterile Pyrex glass
bottles equipped with screw-on caps and
Teflon seals provided by ERGO Research
Laboratory (Hamburg, Germany). The placen-
tal samples, with an average weight of 100 g,
were shipped frozen to the ERGO World
Health Organization (WHO)-certiﬁed labora-
tory for analysis. This laboratory regularly and
successfully participates in interlaboratory
comparison studies, including studies of
PCDDs/PCDFs in beef and ﬁsh liver [National
Institute of Public Health (NIPH) 2001].
Analyses of PCDDs/PCDFs and PCBs.
Analyses of PCDDs/PCDFs and PCBs were
performed according to a previously published
method (Päpke et al. 1998). Brieﬂy, 100 g of
placental sample was extracted with n-pentane
after addition of an internal standard (13C12-
PCDD/PCDF or 13C12-PCB). The lipid con-
tent of breast milk samples was determined
gravimetrically before cleanup in a multi-
column system. The specific congeners of
17 2,3,7,8-substituted PCDDs/PCDFs,
12 dioxin-like PCBs (including non-ortho and
mono-ortho PCBs), and six indicator PCBs
(International Union of Pure and Applied
Chemistry PCB congeners 138, 153, and 180)
were analyzed by gas chromatography with
high-resolution mass spectrometry (HP
GC5890 Series II/VG-AutoSpec; Hewlett
Packard, Bristol, UK). Authentic standards of
native dioxin-like PCBs and PCDDs/PCDFs
were purchased from AkkuStandard Inc.
(New Haven, CT, USA). Indicator PCB stan-
dards were obtained from LGC Promochem
(Wesel, Germany). Two isotope masses were
measured for each component. Quantiﬁcation
was performed using internal/external stan-
dard mixtures via the isotope dilution method.
The limit of detection (LOD) was deﬁned
as the value exceeding the signal-to-noise ratio
by a factor of 3. The limit of quantification
was defined as 2 × LOD. For each block of
samples, individual blanks and laboratory in-
house quality control pools for the various
matrices were analyzed. The SD was 11–15%.
Pools were checked by interlaboratory com-
parisons. Recovery of 13C-labeled internal
standards ranged from 70 to 130%. The toxic
equivalents (TEQs) of PCDDs/PCDFs and
PCBs were calculated according to WHO toxic
equivalent factors (Van den Berg et al. 1998).
Analysis of estrogen and its metabolites.
Each maternal venous serum sample was
hydrolyzed with β-glucuronidase and sulfatase
at 37°C for 16 hr (Mitamura et al. 2000).
Type H-2 β-glucuronidase/sulfatase from
Helix promatia with β-glucuronidase activity
of 110,000 U/mL and sulfatase activity of
4,000 U/mL was purchased from Sigma
Chemical Co. (St. Louis, MO, USA). After
16 hr, the serum mixture was loaded onto a
well of a 96-well C-18 solid-phase extraction
(SPE) plate (Discovery DSC-18 SPE-96 Plate,
100 mg/well; Supelco, Bellefonte, PA, USA)
preconditioned sequentially with methanol
(2 mL) and 5% methanol in water (2 mL).
The C-18 SPE plate was then washed with
5% methanol in water (2 mL), followed by
elution with 100% methanol (2 mL) to
recover the steroids. The resulting methanol
solution was dried under nitrogen and resus-
pended in 50 µL of HPLC mobile phase
before liquid chromatography/tandem mass
spectrometry analysis.
The HPLC system (Mitamura et al. 2000)
consisted of two micropumps (both PE series
200; PerkinElmer, Norwalk, CT, USA) and an
auto-sampler (PE series 200; PerkinElmer)
coupled with a triple-stage quadrupole mass
spectrometer (API 3000; PE-SCIEX, Concord,
ON, Canada). Sample solutions were sepa-
rated on a C-18 column (HyPurity Elite C18,
150 × 2.1 mm, particle size 3 µm; Thermo
Hypersil, Runcorn, UK). Mobile phase A
(50% methanol containing 0.5 mM ammo-
nium formate at pH 4 at a flow rate of
200 µL/min) was used from 0 to 15 min, fol-
lowed by a fast-gradient 100% mobile phase B
(95% methanol containing 0.1% formic acid)
within 5 min. Mobile phase B (100%) was
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Figure 1. Estrogen metabolism and catabolism and potential modiﬁcations by dioxins or dioxin-like com-
pounds. Abbreviations: 3 β-HSD, 3 β-hydroxysteroid dehydrogenase; 17-KSR, 17-ketosteroid reductase;
ARNT, AhR nuclear translocator; COMT, catechol-O-methyl transferase; CYPs, cytochrome P450 enzymes;
DRE, dioxin responsive element; XAP2, hepatitis B virus X-associated protein 2; Hsp90, 90-kDa heat-shock
protein. Solid lines indicate induced CYP1A1 and CYP1A2 enzymes via AhR activation by dioxins and
dioxin-like compounds; dashed lines indicate induced CYP1B1 enzyme via AhR activation by dioxins and
dioxin-like compounds.then maintained for 4 min before a quick
ramp back to 100% mobile phase A. Mobile
phase A was continued for another 16 min
toward the end of analysis. Target analytes
were detected under a multiperiod experiment
alternating between a positive mode (5,000 V)
from 0 to 10 min, negative (–3,800 V) mode
from 10.1 to 24.0 min, and then positive
mode from 24.1 min to the end of the run.
Other parameters were optimized for individ-
ual analytes. Concentrations of the metabo-
lites were calculated using the specific peak
area and corrected with the peak area of the
internal standard (17α-ethynyl estradiol).
Statistical analyses. PCDD/PCDF and
PCB values were transformed to the natural
logarithm and tested for normal distribution
by the Kolmogorov-Smirnov (K-S) method
for parametric analyses. K-S tests for normality
of the exposure data were based on the largest
absolute difference between the observed and
the expected cumulative distributions.
Measurement values < LOD were recorded as
zero in this study. Pearson correlation was used
to assess the association between PCDD/PCDF
levels and various estrogen metabolites. General
linear regression and quadratic models were
performed to evaluate the relations of body bur-
dens of PCDDs/PCDFs and PCBs to levels of
estrogen metabolites. Multivariate analyses were
carried out to distinguish the independent
effects on certain congeners from those of other
covariable congeners. Statistical analyses were
performed using the Statistical Package for
Social Science (SPSS Inc. 2000), version 10.0.7
(SPSS Inc., Chicago, IL, USA).
Results
Subject characteristics and the levels of steroid
hormones, PCDDs/PCDFs, and PCBs. Our
study subjects were pregnant without compli-
cations and had a normal birth outcome, 
prepregnancy body mass index (BMI) within
normal range, and mean age of 28.2 or 30.4
years for those carrying a male or female baby,
respectively (Table 1). Fifty-two percent of the
babies were males. Only three of the women
used to smoke cigarettes; none was a current
smoker. Forty-eight percent of the women
were passively exposed to cigarette smoke on a
daily basis. However, there were no signiﬁcant
differences in either PCDD/PCDF exposure
or serum estrogen concentrations between
women who were identiﬁed as passive smokers
and those who were not. None of the partici-
pants had an alcohol-consumption habit or
had ever farmed or worked near an incinerator
or a chemical factory (potential sources of
PCDD/PCDF exposure). The mean ± SD of
total PCDD/PCDF body burdens was 13.6 ±
5.1 pg WHO-TEQ/g lipid, of which 2.9 pg
was due to dioxin-like PCBs.
Figure 1 shows the steroid hormones
quantified in the present study (in boldface)
and their metabolic pathways. Table 2 shows
serum levels of steroid hormones and the cor-
relations among them. Concentrations of E2
and testosterone were within clinically normal
ranges. Androstenedione, estrone (E1), estriol
(E3), progesterone, 2-OH-E2, and 4-OH-E2
were all significantly correlated in pregnant
women carrying a male fetus, with coefﬁcients
between 0.4 and 0.9. For women carrying a
female fetus, E3 was correlated with E1
(r = 0.56, p < 0.01) and progesterone (r = 0.68,
p < 0.001), whereas 2-OH-E2 was associated
with 4-OH-E2 (r = 0.87, p < 0.001).
Table 3 shows placental levels of PCDDs,
PCDFs, and PCBs in concentrations and TEQs
for 50 subjects. More than 80% of the measure-
ment outcomes were > LODs. The distributions
of each level were slightly skewed to the right
Wang et al.
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Table 1. General characteristics of pregnant women and their infants according to sex of the newborns.
Male (n = 26) Female (n = 24)
Characteristics (mean ± SD)a (mean ± SD)a
Continuous variable
Age (years) 28.2 ± 3.18 30.4 ± 3.67
Prepregnant body mass index (kg/m2) 22.0 ± 3.43 22.8 ± 4.24
Gestational age (weeks) 39.0 ± 1.50 38.7 ± 1.49
Baby birth weight (g) 3,251 ± 382 2,958 ± 393
Baby birth length (cm) 51.6 ± 2.59 50.9 ± 2.63
Baby head circumference (cm) 33.9 ± 1.23 33.0 ± 1.46
Placental weight (g) 629 ± 141 579 ± 184
Fat content of placenta (%) 0.74 ± 0.12 0.77 ± 0.084
Categorical variable
Cigarette smoking, n (%) 1 (3.85) 2 (8.33)
Passive smoking, n (%) 13 (50.0) 11 (45.8)
Alcohol drinking, n (%) 0 (0.0) 0 (0.0)
Potential dioxin-exposed occupation, n (%) 0 (0.0) 0 (0.0)
No difference between sexes was statistically signiﬁcant.
aValues are mean ± SD except where indicated.
Table 2. Mean levels of steroid hormones and estrogen metabolites and the correlations among them in serum from pregnant women at third trimester according
to fetal sex.
Pearson correlation coefﬁcients (male, n = 26; female, n = 24)
GM 95% CI 4-OH-E2: 4-OH-E2: 2-OH-E2:
Hormone (ng/mL) (ng/mL) E1 E3 Progesterone 2-OH-E2 4-OH-E2 2-OH-E2ratio E2 Testosterone E2 ratio E2 ratio
Androstenedione M 10.4 6.70–12.2 0.572** 0.663# 0.584# 0.691# 0.766# 0.356 –0.380 –0.198 0.567** 0.542*
F 10.4 7.29–14.8 0.255 0.319 0.087 0.586** 0.556** 0.140 0.048 0.603* 0.339 0.393
E1 M 69.4 49.1–98.0 0.678# 0.512** 0.389* 0.440* 0.226 –0.124 0.109 0.501* 0.434
F 59.3 41.6–84.6 0.558** 0.203 0.050 –0.153 –0.399 0.243 0.096 –0.267 –0.004
E3 M 367 201–611 0.800# 0.555# 0.632** 0.332 –0.097 0.064 0.561* 0.447
F 296 206–423 0.679# 0.092 0.022 –0.111 0.220 0.229 –0.024 0.175
Progesterone M 30.9 23.1–41.4 0.441* 0.545* 0.381 –0.171 –0.259 0.765# 0.687**
F 34.1 25.1–46.2 –0.190 0.026 0.376 0.126 0.584* –0.343 –0.293
2-OH-E2 M 1.42 0.776–2.07 0.931# 0.028 –0.259 –0.307 0.738** 0.681**
F 1.44 0.984–2.11 0.873** 0.083 –0.348 0.032 0.774** 0.938#
4-OH-E2 M 0.680 0.451–1.31 0.391* –0.177 –0.175 0.652** 0.571*
F 0.783 0.496–1.24 0.558** –0.382 0.097 0.930# 0.846#
4-OH-E2:2-OH-E2 M 0.479 0.412–0.556 0.121 0.285 0.050 –0.033
F 0.544 0.435–0.680 –0.074 0.164 0.325 –0.169
E2 M 5.56 4.16–7.42 0.703 –0.534** –0.661*
F 5.15 4.10–6.48 0.216 –0.249 –0.466
Testosterone M 9.46 6.97–12.8 –0.575 –0.603
F 7.28 5.16–10.3 –0.417 –0.279
Abbreviations: CI, conﬁdence interval; F, female; GM, geometric mean; M, male.
*p< 0.05, **p< 0.01, and #p< 0.001 by Pearson correlation analyses.because geometric means were generally smaller
than the middle of upper and lower limits.
Relations of steroid hormones to levels of
PCDDs/PCDFs and PCBs. Pearson correlation
results revealed a highly negative relation of
4-OH-E2:2-OH-E2 to the concentrations of
TCDD, 1,2,3,7,8-pentaCDD, and total
PCDD (Table 4). We also found a signiﬁcantly
positive relationship between the levels of high-
chlorinated PCDFs, namely, 1,2,3,4,5,6,7-
heptaCDF and 2-OH-E2. Multivariate results
showed that the significant association
between TCDD and 4-OH-E2:2-OH-E2 ratio
(r = –0.111) remained significant (and also
the association between 1,2,3,7,8-pentaCDD
and 4-OH-E2:2-OH-E2, r = –0.308) after
the adjustment for PCDFs, PCBs, and the
mother’s age (Table 5). In addition,
1,2,3,6,7,8-heptaCDF levels were associated
with increased 2-OH-E2 concentration after
the adjustment for dioxins, PCBs, and the
mother’s age.
The ratio of 4-OH-E2 to 2-OH-E2
decreased with increasing tertile levels of
TCDD from 0.74 [95% confidence interval
(CI), 0.58–0.89], to 0.48 (95% CI,
0.39–0.56), to 0.46 (95% CI, 0.37–0.55)
(p < 0.001, β = –0.16, R = 0.45 by general lin-
ear regression; data not shown). Observed
TCDD concentrations and levels of 2-OH-E2
and 4-OH-E2 are shown in Figure 2. Linear
and quadratic models could describe the
decreasing levels of 4-OH-E2:2-OH-E2 ratio
and 4-OH-E2, respectively, with increasing
TCDD. The β-value of the quadratic term is
not statistically signiﬁcant, and thus the linear
negative association is clear. Figure 2 also
shows the plot for 2-OH-E2 and 4-OH-E2
levels against TCDD concentration. 4-OH-E2
is negatively and signiﬁcantly associated with
increasing TCDD level (Figure 2B); there is
no significant association between 2-OH-E2
and TCDD (Figure 2A). 4-OH-E2:2-OH-E2
and 2-OH-E2 were positively associated with
1,2,3,4,6,7,8-heptaCDF level, according to a
quadratic model. However, neither achieved
statistical signiﬁcance (data not shown).
We also evaluated 2-MeO-E2 and
4-MeO-E2 in maternal venous serum. Only
8 of the 50 samples investigated had 2- and
4-MeO-E2 concentrations > LOD in serum.
This could be reasonable because MeO-E2
might normally be efficiently excreted from
the body in urine.
Discussion
This is the first report on the association of
human body burdens of PCDDs/PCDFs and
PCBs with estrogen metabolites. The informa-
tion presented is crucial to understand their
hormonally related health effects in women,
such as the risk for breast cancer. The relation
between estrogen levels and exposure to
PCDDs/PCDFs and PCBs has been histori-
cally difficult to investigate because of the
marked variation in hormone levels during the
menstrual cycle. To circumvent this difﬁculty,
we used blood drawn at the third trimester
of pregnancy, as suggested previously by
Augustowska et al. (2003).
Altered estrogen metabolism in relation to
dioxins and the mechanism. The observation
of decreased E2 concentrations with increasing
TCDD and pentaCDD levels is consistent
with the known antiestrogenic properties of
TCDD (Safe 2001). We have further demon-
strated that decreased 4-OH-E2:2-OH-E2
ratios and decreased 4-OH-E2 levels are corre-
lated with increasing TCDD level, after the
adjustment of other congener exposure and
maternal age. Similar results have been
obtained from a study of MCF-7 and
MCF-10A cells (van Duursen et al. 2003).
The above observation might imply that
4-hydroxylation is a minor pathway (Figure 1)
relative to 2-hydroxylation for estrogen
metabolism in women with higher TCDD
Dioxins and estrogen metabolism
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Table 3. Body burdens of polychlorinated PCDDs, PCDFs, and PCBs in concentrations and TEQs (n = 50).
Concentration (pg/g lipid) TEQ (pg-TEQ/g lipid)
Congeners n/na Geometric mean 95% CI Geometric mean 95% CI
PCDDs (n = 7) 348/350 191 167–217 5.37 4.84–5.97
PCDFs (n = 10) 405/500 30.6 22.8–41.1 4.40 3.91–4.95
Non-ortho PCBs (n = 4) 162/200 30.8 25.5–37.2 1.41 1.09–1.81
Mono-ortho PCBs (n = 8) 356/400 4,330 3,660–5,130 1.38 0.347–5.50
Total TEQs 1,271/1,450 — — 12.8 11.5–14.1
Indicator PCBsb (n = 3) 142/150 21,300 17,100–26,800 — —
CI, conﬁdence interval. 
aNumber of detectable compounds/number of total compounds. bThe sum of PCB congeners 138, 153, 180.
Table 4. Correlations between body burdens of PCDDs, PCDFs, and PCBs their relations to steroid hormones in maternal venous serum.
Total Total Total Total indicator
Exposure hormone TCDD 1,2,3,7,8-PentaCDD Total PCDDs 1,2,3,4,6,7,8-HeptaCDF Total PCDFs WHO-TEQs non-ortho-PCBs mono-ortho-PCBs PCBs
Androstenedione (ng/mL) –0.058 0.038 –0.035 0.175 0.062 0.022 –0.002 0.067 0.095
E1 (ng/mL) –0.122 0.038 –0.091 0.257 0.085 0.016 –0.018 0.155 0.262
E3 (ng/mL) 0.053 0.263 0.151 0.114 0.182 0.110 –0.105 –0.063 0.013
Progesterone (ng/mL) 0.073 0.303* 0.239 0.017 0.246 0.242 0.000 0.184 0.123
2-OH-E2 (ng/mL) –0.013 0.080 0.017 0.281* 0.076 0.048 0.004 0.036 0.006
4-OH-E2 (ng/mL) –0.222 –0.121 –0.177 0.204 –0.115 –0.146 –0.039 –0.038 –0.043
E2 –0.309* –0.313* –0.302* 0.116 –0.258 –0.237 0.028 0.024 0.112
Testosterone –0.099 –0.099 –0.098 –0.064 –0.075 –0.048 0.122 –0.030 0.036
4-OH-E2:2-OH-E2 –0.400** –0.316* –0.342* 0.078 –0.297* –0.317* –0.098 –0.044 0.027
*p< 0.05, and **p< 0.01 by Pearson correlation analyses.
Table 5. Linear regression coefﬁcients for predicting E2 metabolites by PCDDs, PCDFs, and PCBs.
Total Total Total indicator
Exposure hormone TCDD 1,2,3,7,8-PentaCDD 1,2,3,4,6,7,8-HeptaCDF non-ortho-PCBs mono-ortho-PCBs PCBs R2
Model group 1
2-OH-E2 (ng/mL) — 0.168 0.366* –0.129 0.055 –0.038 0.118
4-OH-E2 (ng/mL) — –0.066 0.225 –0.118 0.052 –0.064 0.059
4-OH-E2:2-OH-E2 — –0.308* 0.036 –0.114 –0.036 0.101 0.116
Model group 2
2-OH-E2 (ng/mL) 0.161 — 0.398* –0.167 0.054 –0.021 0.111
4-OH-E2 (ng/mL) –0.160 — 0.164 –0.078 0.096 –0.108 0.073
4-OH-E2:2-OH-E2 –0.111* — –0.097 –0.005 0.034 0.011 0.169
TCDD and 1,2,3,7,8-pentaCDD were so highly correlated that one of them was used in either model group 1 or 2 to prevent overadjustment.
*p < 0.05 by multiple general linear regression analyses adjusted for other congener and maternal age.exposure. 4-OH-E2 is a strong carcinogen in
comparison with 2-OH-E2 because 4-OH-E2
readily forms free radicals, such as superoxide
and reactive semiquinone intermediates, via
metabolic redox reactions. These free radicals
may attack DNA and induce normal cells to
undergo transformation into neoplastic cells
(Zhu and Conney 1998). The lower 4-OH-E2
level, which correlated with TCDD exposure,
suggests that TCDD has already modified
4-hydroxylation. This may or may not imply
that TCDD reduced the carcinogenicity of
estrogens. Notably, estrogen metabolism is
governed by different cytochrome P450
enzymes in different types of cells. For
instance, the CYP3A family is responsible for
estrogen 4-hydroxylation in human liver
(Kerlan et al. 1992), whereas CYP1B1 is the
key 4-hydroxylation enzyme in human breast
(Hayes et al. 1996) and uterus (Liehr et al.
1995). In addition, CYP gene expression in
response to TCDD exposure may differ
between cell types (Dohr et al. 1995; Kress and
Greenlee 1997). The level of serum 4-OH-E2,
which is mainly derived from hepatic metabo-
lism, may not represent local tissue concentra-
tions. The tissue-speciﬁc effects of TCDD on
4-OH-E2 productions, particularly those in
extrahepatic target tissues, warrant future
studies. For identiﬁcation of the group at high
cancer risk, present results might imply that the
threshold of the cancer risk marker (4-OH-E2
or 4-OH-E2:2-OH-E2) might be lowered in
those exposed to high levels of dioxin.
Another possibility to be considered is that
TCDD exposure largely increased the capabil-
ity of catechol-O-methyl transferase (COMT)
to metabolize 4-OH-E2 to 4-MeO-E2. The
signiﬁcant reduction in 4-OH-E2 level along
with TCDD exposure may then be due to a
rapid subsequent metabolism and excretion of
this compound. However, no biochemical evi-
dence to date indicates that COMT uses
2-OH-E2 differently from 4-OH-E2 or that
TCDD inﬂuences COMT metabolism. This
deserves further investigation.
The present data highlight the complica-
tions that can arise in human studies of multi-
congener exposure. For example, body burden
of 1,2,3,4,6,7,8-heptaCDF was positively
associated with serum levels of 2-OH-E2, after
the adjustment for other congeners and mater-
nal age. Further study of experimental design
with single and/or multiple congener treat-
ment would be helpful for confirming the
observation. There was no signiﬁcant correla-
tion between estrogen metabolites and PCBs.
This might reﬂect the reduced potency of PCB
congeners to induce CYP1A1 and CYP1B1
(van Duursen et al. 2003).
The quadratic model reasonably described
the negative association between TCDD body
burden and 4-OH-E2 level. This might indi-
cate that 4-OH-E2 tends to reach a plateau and
even increase, whereas TCDD concentrations
continue to increase beyond 5 pg/g lipid. This
may be due to saturation of the AhR or feed-
back in response to decreased E2 level. The
hypothalamus may secrete gonadotropin-
releasing hormone and thus cause the ovary to
produce E2 through the pituitary (Palter and
Olive 1996).
Other speculations and suggestions for fur-
ther study. Placental levels of PCDDs/PCDFs
and PCBs in the present study were similar to
those we reported previously, with 13 pg-
WHO-TEQ/g lipid (Wang et al. 2004), and
much lower than that reported for 21 women
in Japan, with 31 pg-WHO-TEQ/g lipid
(Suzuki et al. 2005). Our TEQ data and those
of an earlier study of five New York women
(Schecter et al. 1998) are relatively similar,
although sample size and age of participants
are different. The placental levels were much
higher in Yu-Cheng PCB-exposed mothers
(Schecter et al. 1996) than in those from
Taiwan (Wang et al. 2004), Japan (Suzuki
et al. 2005), and the United States (Schecter
et al. 1996), as expected. More data might be
necessary to draw solid conclusions on the
comparisons among general populations.
The consistent observation that 2-OH-E2
and 4-OH-E2 concentrations were highly
correlated is reasonable because both are
metabolites of E1 and E2. This is also the case
for the correlation of androstenedione with
E1 and E3. Study of hormone profiles from
the same subject may reduce data variation
and help conclusions to be drawn, even with
a limited sample size. When dividing the
group according to infant sex, more correla-
tions with estrogen metabolites appeared for
women carrying male than female fetuses.
This is of interest; however, when associating
the estrogen metabolite levels with levels of
PCDDs/PCDFs and PCBs, the sex difference
was not signiﬁcant.
In the present study, the total concentra-
tions of both conjugated and free forms of
estrogens were measured according to con-
ventional methods. All women we examined
showed detectable levels of 2- and 4-OH-E2.
Many in vitro studies could not present such
information, probably because of the efﬁcient
COMT-mediated metabolic conversion of
OH-E2 to MeO-E2 (Oeltmann et al. 2004).
Previous studies of cultured human mam-
mary epithelial cells indicate that TCDD
may induce expression of the CYP1A1 and
CYP1B1 genes and catechol-estrogen–mediated
oxidative DNA damage (Chen et al. 2004).
Epidemiologic evidence also supports a role
for oxidative metabolites, particularly for cate-
chol estrogens such as 4-OH-E2 (Russo et al.
2003), in initiation of breast cancer (Mitrunen
and Hirvonen 2003). Thus, we suggest that
OH-E2 rather than MeO-E2 should be meas-
ured directly when studying the health effects
of dioxin and dioxin-like compound exposure.
Methodologic considerations. Possible
confounders that might agonize AhR activity
and alter estrogen metabolism were closely
evaluated, including occupation, smoking,
and cooking habits. In general, fat tissue
tends to be mobilized more in pregnant than
in nonpregnant women. This may provide a
window for observing the interrelationships
between lipophilic compounds.
Conclusion
In conclusion, we found significantly and
independently decreasing serum 4-OH-
E2:2-OH-E2 ratios correlated with increasing
TCDD exposure level. If TCDD is indeed a
human carcinogen, then the present results
imply that the congener profile should be
taken into account and evaluated, in addition
to genotype, to assess vulnerability and iden-
tify the groups at high risk for cancer, and
that the threshold for the cancer risk marker
4-OH-E2:2-OH-E2 might be lowered in
those exposed to high levels of dioxin.
Wang et al.















































































































Figure 2. Relations of TCDD concentration to 2-OH-E2 concentration [A, left axis; –0.04(TCCD) + 2.28 (p =
0.93, R2 = 0.0002); quadratic model = 0.37(TCDD)2 – 1.8(TCDD) + 4.03 (p = 0.66; R2 = 0.02)], 4-OH-E2:2-OH-E2
ratio [A, right axis; –0.124(TCCD) + 0.82 (p = 0.004, R2 = 0.16); quadratic model = 0.09(TCDD)2 – 0.55(TCDD) +
1.25 (p = 0.001; R2 = 0.27)], and 4-OH-E2 concentrations [B;  –0.42(TCCD) + 2.09 (p = 0.12, R2 = 0.05); quadratic
model = 0.43(TCDD)2 – 2.39(TCDD) + 4.10 (p = 0.06; R2 = 0.12)].Dioxins and estrogen metabolism
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